Ultrasound sales to post healthy growth
Innovations in radiology and cardiology will boost the U.S. ultrasound market over the next three years, according to a study conducted by Datamonitor, a market analysis firm specializing in the medical equipment and healthcare industries. Ultrasound
Innovations in radiology and cardiology will boost the U.S. ultrasound market over the next three years, according to a study conducted by Datamonitor, a market analysis firm specializing in the medical equipment and healthcare industries. Ultrasound should see a compound annual growth rate of approximately 7% over the next five years and will climb from its current $943 million market to $1.2 billion by 2003, Datamonitors Trends and Dynamics in U.S. Ultrasound 1999 report claims. Ultrasounds radiology segment represents about 40% of the overall ultrasound market, while cardiology represents about 35%, according to the report.
Acuson, Philips/ATL Ultrasound, and Hewlett-Packard are the top three companies in ultrasound, with GE Medical Systems and Toshiba America Medical Systems ranked next, according to the New York-based firm.
Although ultrasound sales have traditionally been driven by mid-range systems, this segment is now the smallest in both revenue and volume, since its technology has begun trickling down to low-end systems. Datamonitor predicts that although all segments of the ultrasound market will see growth, sales of high-end radiology and cardiology units will particularly increase, as their technology becomes more capable of competing with such other imaging modalities as MRI and CT.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
